We need to get this board going again. This is a great company! It doesn't deserve to be selling so cheap! The worst is over with the Chinese Small Cap Pharmaceutical Sector. This is going to be one of the solid performers in the future. Good balance sheet, cash and earnings, good pipeline, good institutional following plus book value much higher than the stock price.